<DOC>
	<DOCNO>NCT01599325</DOCNO>
	<brief_summary>The purpose study determine whether azacitidine safe effective treatment Chinese patient high risk Myelodysplastic Syndromes ( MDS ) .</brief_summary>
	<brief_title>Study Azacitidine Evaluate Safety Effectiveness Chinese Patients With Higher Risk Myelodysplastic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Subjects must satisfy follow criterion enrol study : Chinese male female Asian descent ≥ 18 year age time sign informed consent document ; Must document diagnosis refractory anemia excess blast ( RAEB ) refractory anemia excess blast transformation ( RAEBT ) accord FrenchAmericanBritish ( FAB ) classification Myelodysplastic Syndrome ( MDS ) International Prognostic Scoring System ( IPSS ) score intermediate2 high risk diagnosis myelodysplastic chronic myelomonocytic leukemia ( CMML ) per modify FAB criterion meet follow : Monocytosis peripheral blood &gt; 1 x 10^9/L ; Dysplasia one myeloid cell line ; 10 % 29 % blast bone marrow ; White blood cell ( WBC ) count &lt; 13 x 10^9/L Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 ; Adequate organ function , define : Serum bilirubin ≤ 1.5 time upper limit normal ( ULN ) ; Serum aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 2.0 time ULN ; Serum Creatinine ≤ 1.5 time ULN ; Females childbearing potential ( FCBP ) must : Agree use physicianapproved contraceptive method ( oral , injectable , implantable hormonal contraceptive ; tubal ligation ; intrauterine device ; barrier contraceptive spermicide ; vasectomized partner ) azacitidine ; 3 month follow last dose azacitidine ; negative serum pregnancy test within 72 hour prior start Investigational Product ( IP ) . Male subject female partner childbearing potential must agree use physicianapproved contraceptive method throughout course study avoid father child course study 3 month follow last dose azacitidine ; Understand voluntarily sign informed consent document prior study related assessments/procedures conduct ; Able adhere study visit schedule protocol requirement . The presence follow exclude subject enrollment : Previous treatment azacitidine decitabine ; Diagnosis malignant disease within previous 12 month ( exclude basal cell carcinoma skin without complication , `` insitu '' carcinoma cervix breast , local malignancy excise irradiated high probability cure ) ; Uncorrected red cell folate deficiency vitamin B12 deficiency ; Diagnosis metastatic disease ; Malignant hepatic tumor ; Known suspect hypersensitivity azacitidine mannitol ; Candidate proceed bone marrow stem cell transplant study ; Prior transplantation cytotoxic therapy , include azacitidine chemotherapy , administer treat MDS ; Treatment erythropoietin myeloid growth factor ( granulocyte colonystimulating factor [ GCSF ] granulocytemacrophage colonystimulating factor [ GMCSF ] ) 21 day prior Day 1 Cycle 1 ; Treatment androgenic hormone 14 day prior Day 1 Cycle 1 ; Active viral infection know human immunodeficiency virus ( HIV ) viral hepatitis type B C ; Treatment investigational drug , include thalidomide arsenic trioxide , within previous 30 day prior Day 1 Cycle 1 , ongoing adverse event previous treatment investigational drug , regardless time period ; Pregnant lactating female ; Any significant medical condition , laboratory abnormality , psychiatric illness would prevent subject participate study ; Any condition include presence laboratory abnormality , place subject unacceptable risk he/she participate study ; Any condition confound ability interpret data study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>